Santhera Pharmaceuticals Holding AG - Asset Resilience Ratio

Latest as of December 2023: 27.70%

Santhera Pharmaceuticals Holding AG (SANN) has an Asset Resilience Ratio of 27.70% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Santhera Pharmaceuticals Holding AG (SANN) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF30.37 Million
≈ $38.40 Million USD Cash + Short-term Investments

Total Assets

CHF109.63 Million
≈ $138.60 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2024)

This chart shows how Santhera Pharmaceuticals Holding AG's Asset Resilience Ratio has changed over time. See Santhera Pharmaceuticals Holding AG (SANN) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Santhera Pharmaceuticals Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SANN market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF30.37 Million 27.7%
Short-term Investments CHF0.00 0%
Total Liquid Assets CHF30.37 Million 27.70%

Asset Resilience Insights

  • Very High Liquidity: Santhera Pharmaceuticals Holding AG maintains exceptional liquid asset reserves at 27.70% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Santhera Pharmaceuticals Holding AG Industry Peers by Asset Resilience Ratio

Compare Santhera Pharmaceuticals Holding AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Santhera Pharmaceuticals Holding AG (2006–2024)

The table below shows the annual Asset Resilience Ratio data for Santhera Pharmaceuticals Holding AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 14.82% CHF22.59 Million
≈ $28.57 Million
CHF152.49 Million
≈ $192.79 Million
-5.11pp
2023-12-31 19.92% CHF21.84 Million
≈ $27.62 Million
CHF109.63 Million
≈ $138.60 Million
-3.35pp
2021-12-31 23.28% CHF21.21 Million
≈ $26.81 Million
CHF91.12 Million
≈ $115.20 Million
+24.64pp
2018-12-31 -1.36% CHF-1.50 Million
≈ $-1.90 Million
CHF110.29 Million
≈ $139.44 Million
-13.21pp
2017-12-31 11.85% CHF13.01 Million
≈ $16.45 Million
CHF109.78 Million
≈ $138.79 Million
-43.02pp
2016-12-31 54.87% CHF49.81 Million
≈ $62.98 Million
CHF90.79 Million
≈ $114.79 Million
+54.81pp
2007-12-31 0.06% CHF81.00K
≈ $102.41K
CHF144.18 Million
≈ $182.28 Million
-0.11pp
2006-12-31 0.16% CHF263.00K
≈ $332.50K
CHF162.39 Million
≈ $205.31 Million
--
pp = percentage points

About Santhera Pharmaceuticals Holding AG

SW:SANN Switzerland Biotechnology
Market Cap
$305.63 Million
CHF241.74 Million CHF
Market Cap Rank
#15771 Global
#167 in Switzerland
Share Price
CHF17.00
Change (1 day)
-5.87%
52-Week Range
CHF9.58 - CHF18.54
All Time High
CHF1070.00
About

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more